Literature DB >> 12744900

Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity.

John D Shanley1, Carol A Wu.   

Abstract

The murine cytomegalovirus (MCMV) glycoprotein B (gB) gene was expressed in an adenovirus replication-deficient vector. This virus, designated Ad-gB, was used to immunize BALB/c and B6 mice by the intranasal (i.n.) route to induce an immune response. Following primary immunization, antibody was detected in serum of 100% of vaccinees, as well as the bronchoalveolar lavage, fecal suspensions and vaginal washings. The viral titer of lung and salivary gland of vaccinees 10 days after intranasal challenge with MCMV at 10(5) or 10(3)plaque forming units (PFU) were significantly reduced compared to controls. Re-exposure of vaccinees to Ad-gB 30 days after primary immunization induced a remarkable boost of serum and mucosal antibody responses and further reduction of MCMV titers in the lung and salivary glands. The ability to induce both a systemic and mucosal immune response to a specific gene product may be important in reducing horizontal transmission of CMV infections across mucosal surfaces and in altering host immunity to CMV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744900     DOI: 10.1016/s0264-410x(03)00037-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Protective MCMV immunity by vaccination of the salivary gland via Wharton's duct: replication-deficient recombinant adenovirus expressing individual MCMV genes elicits protection similar to that of MCMV.

Authors:  Guangliang Liu; Fangfang Zhang; Ruixue Wang; Lucille London; Steven D London
Journal:  FASEB J       Date:  2014-01-03       Impact factor: 5.191

2.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 3.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

4.  A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.

Authors:  Christian Andreas Mohr; Jurica Arapovic; Hermine Mühlbach; Marc Panzer; Annelies Weyn; Lars Dölken; Astrid Krmpotic; David Voehringer; Zsolt Ruzsics; Ulrich Koszinowski; Torsten Sacher
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

Review 5.  Update on the current status of cytomegalovirus vaccines.

Authors:  Heungsup Sung; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

6.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

7.  Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.

Authors:  Steven R Wilson; Jean H Wilson; Linda Buonocore; Amy Palin; John K Rose; Jon D Reuter
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

Review 8.  Cytomegalovirus vaccine development.

Authors:  M R Schleiss
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

9.  Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.

Authors:  Lin Xia; Ruopeng Su; Zhiqiang An; Tong-Ming Fu; Wenxin Luo
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

10.  Salivary gland immunization via Wharton's duct activates differential T-cell responses within the salivary gland immune system.

Authors:  Guangliang Liu; Fangfang Zhang; Ruixue Wang; Steven D London; Lucille London
Journal:  FASEB J       Date:  2019-02-28       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.